IMUX

NASDAQ open

Immunic

7.08 USD
▼-0.31-4.19%
盘后 7.43 0.00%
2026-11-20
市值
$95.37M
市盈率
—
EPS
-3.80
股息率
—
52 周区间
5.06 – 17.43
成交量
199.66K
Beta
1.48
目标价
42.55
52W 低 5.0652W 高 17.43
价格走势

公司简介

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patien...